PepGen (NASDAQ:PEPG) Price Target Raised to $15.00

PepGen (NASDAQ:PEPG – Free Report) had its price objective increased by Guggenheim from $7.00 to $15.00 in a research report sent to investors on Friday,Benzinga reports. Guggenheim currently has a buy rating on the stock.

Other equities analysts have also issued reports about the stock. Bank of America upgraded shares of PepGen from an “underperform” rating to a “neutral” rating and raised their price objective for the company from $2.50 to $6.00 in a research report on Tuesday, November 10th. Wall Street Zen raised shares of PepGen from a “sell” rating to a “hold” rating in a report on Saturday, November 7th. Wedbush upped their target price on shares of PepGen from $4.00 to $10.00 and gave the stock an “outperform” rating in a report on Wednesday, November 11th. HC Wainwright reiterated a “buy” rating on shares of PepGen in a research note on Wednesday, September 9th. Finally, Weiss Ratings raised shares of PepGen from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, September 22nd. Five analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, PepGen presently has a consensus rating of “Moderate Buy” and a consensus target price of $11.40.

Check Out Our Latest Research Report on PepGen

PepGen Price Performance

PEPG stock opened at $4.36 on Friday. The firm has a market capitalization of $301.97 million, a PE ratio of -4.07 and a beta of 2.02. PepGen has a twelve month low of $1.31 and a twelve month high of $7.80. The stock has a 50-day simple moving average of $2.80 and a two-hundred day simple moving average of $2.97.

PepGen (NASDAQ:PEPG – Get Free Report) last announced its quarterly earnings results on Tuesday, November 10th. The company reported ($0.28) earnings per share for the quarter, missing the consensus estimate of ($0.27) by ($0.01). On average, equities research analysts anticipate that PepGen will post -1.13 EPS for the current fiscal year.

Institutional Trading of PepGen

Several institutional investors and hedge funds have recently modified their holdings of the business. Commodore Capital LP grew its holdings in shares of PepGen by 31.6% during the first quarter. Commodore Capital LP now owns 4,475,000 shares of the company’s stock worth $7,921,000 after purchasing an additional 1,075,000 shares in the last quarter. Marshall Wace LLP increased its position in shares of PepGen by 136.3% in the third quarter. Marshall Wace LLP now owns 2,049,112 shares of the company’s stock worth $4,959,000 after purchasing an additional 1,182,120 shares during the last quarter. ADAR1 Capital Management LLC bought a new position in shares of PepGen in the second quarter worth approximately $4,664,000. AWM Investment Company Inc. raised its stake in PepGen by 201.1% in the third quarter. AWM Investment Company Inc. now owns 1,806,419 shares of the company’s stock valued at $4,372,000 after purchasing an additional 1,206,419 shares in the last quarter. Finally, BlackRock Inc. purchased a new stake in PepGen in the second quarter valued at approximately $2,348,000. Hedge funds and other institutional investors own 58.01% of the company’s stock.

PepGen Company Profile

(Get Free Report)

PepGen is a clinical-stage biotechnology company developing oligonucleotide medicines for people with neuromuscular diseases. Its Enhanced Delivery Oligonucleotide (EDO) platform is designed to help deliver these medicines to muscle tissue. The company’s pipeline includes PGN-EDO51, an investigational exon-skipping therapy for Duchenne muscular dystrophy in patients whose genetic mutations are amenable to exon 51 skipping, and PGN-EDODM1, an investigational candidate for myotonic dystrophy type 1.

Further Reading

Analyst Recommendations for PepGen (NASDAQ:PEPG)

Receive News & Ratings for PepGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PepGen and related companies with MarketBeat.com's FREE daily email newsletter.